When was Cidara Therapeutics founded?

Cidara Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Cidara Therapeutics located?

Cidara Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California.

Who is the current CEO of Cidara Therapeutics?

Jeff Stein of Cidara Therapeutics.

How many employees does Cidara Therapeutics have?

As of Apr 30, 2026, the latest employee count at Cidara Therapeutics is 53.

Is Cidara Therapeutics a funded company?

Cidara Therapeutics is a funded company, having raised a total of $78.4M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 16, 2014.

When was the latest funding round of Cidara Therapeutics?

Cidara Therapeutics' latest funding was a $***** Post IPO round on Nov 21, 2024, with participation from 8 investors. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $957M in funding in 2026 to date.

What is the annual revenue of Cidara Therapeutics?

Annual revenue of Cidara Therapeutics is $1.27M as on Dec 31, 2024.

Where does Cidara Therapeutics rank among its competitors?

Cidara Therapeutics ranks 199th amongst 2747 active competitors, of which 921 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Cidara Therapeutics?

Cidara Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Karyopharm secured the most recent funding round in March, 2026.

Cidara Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Cidara Therapeutics is an acquired company based in San Diego (United States), founded in 2013. It operates as a Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Cidara Therapeutics has raised $78.4M in funding from investors like 5AM Ventures, Fidelity Investments and InterWest Partners. The company has 2747 active competitors, including 921 funded and 668 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.

Website: cidara.com
Social
Email ID: *****@cidara.com
Registered Address: San Diego, California

Key Metrics

Founded Year

2013

Location

San Diego, United States

Stage

Acquired

Total Funding

$78.4M in 8 rounds

Latest Funding Round

Post IPO, Nov 21, 2024, $*****

Investors

5AM Ventures & 24 more

Ranked

199^th among 2747 active competitors

Annual Revenue

$1.27M as on Dec 31, 2024

Employee Count

53 as on Apr 30, 2026

Similar Companies

BeiGene & 525 more

Exit Details

Acquired by Merck (Nov 14, 2025)

View Cidara Therapeutics' full profile

Cidara Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cidara Therapeutics, Inc. CIN: 461537286 , United States, Active	May 31, 2013	$1.27M (As on Dec 31, 2024)	40 (As on Dec 31, 2024)	-

Cidara Therapeutics got acquired by Merck on Nov 14, 2025.

Click here to take a look at Cidara Therapeutics's acquisition in detail

Cidara Therapeutics has raised a total funding of $78.4M over 8 rounds. Its first funding round was on Jun 16, 2014. Its latest funding round was a Post IPO round on Nov 21, 2024 for $*****. 8 investors participated in its latest round. Cidara Therapeutics has 25 institutional investors.

Here is the list of recent funding rounds of Cidara Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 21, 2024	7760064	Post IPO	8382362	3849860	8172103	3997189
Apr 24, 2024	9178791	Post IPO	4176889	7065616	3638318	5877841
Sep 12, 2019	3514335	Post IPO	5385312	5650757	8338272	1441956

Access funding benchmarks and valuations. Sign up today!

View details of Cidara Therapeutics's funding rounds and investors

Cidara Therapeutics' employee count trend

Cidara Therapeutics has 53 employees as of Apr 26. Here is Cidara Therapeutics's employee count trend over the years:

Employee count trend for Cidara Therapeutics

Uncover Cidara Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cidara Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Cidara Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
10th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
199th	Cidara Therapeutics 2013, San Diego (United States), Acquired	Developer of novel anti-infectives for infectious diseases (bacterial and fungal)	$78.4M	Fidelity Investments, BVF Partners & 23 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Cidara Therapeutics's competitors? Click here to see the top ones

Cidara Therapeutics has made no investments or acquisitions yet.

Media has covered Cidara Therapeutics for a total of 26 events in the last 1 year, 11 of them have been about company updates and 1 about partnerships.